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Background There is no consensus whether early administration of unfractionated heparin (UFH) is beneficial in pts prior to mechanical 
reperfusion for STEMI. We assessed outcomes of pts in HORIZONS-AMI trial in relation to UFH administration prior to randomization to bivalirudin 
(Biv) or UFH+a glycoprotein IIb/IIIa inhibitor (GPI).
Methods and Results In HORIZONS-AMI, randomization was stratified by the administration of UFH in the ER pre enrollment. Among a total of 
3595 pts, 2357 pts received UFH pre randomization to Biv (n=1178) or to UFH+GPI (n=1179). A total of 1238 pts were not administered UFH pre 
randomization (619 pts in each arm). Administration of UFH pre randomization was associated with older age, > frequent use of clopidogrel loading 
dose of 600 mg, and > treated lesions. Pts who were administered UFH pre randomization had higher incidence of TIMI flow grade 2/3 on baseline 
both in Biv arm (37% vs 26%, p<0.0001) and UFH+GPI arm (39% vs 29%, p<0.0001). There was a significant interaction (Table) between UFH 
administration pre randomization and pharmacologic assignment; 30-day rates of MACE and NACE were significantly improved in Biv pts (but not 
UFH+GPI pts) who received UFH in the ER, without increase in major bleeding.
Conclusion In the HORIZONS-AMI trial, administration of UFH pre randomization to Biv or UFH+GPI was associated with reduced ischemic 
complications without an increase in bleeding events, benefits that were especially evident in pts treated with a bivalirudin monotherapy strategy. 
30-day outcomes, %
Patients with STEMI
n=3595
Bivalirudin monotherapy
n=1797
HR [95%CI]
UFH + GPI
n=1798
HR [95%CI] P interactionPre-randomization 
UFH (+)
n=1178
Pre-randomization 
UFH (-)
n=619
Pre-
randomization 
UFH (+)
N=1179
Pre-
randomization 
UFH (-)
N=619
Death 2.0% 2.3% -0.31 [-1.72,1.11] 3.2% 2.9% 0.32 [-1.35,1.99] 0.57
Reinfarction 1.5% 2.6% -1.07 [-2.52,0.38] 2.0% 1.5% 0.51 [-0.74,1.76] 0.09
Ischemic TVR 1.8% 3.9%
-2.11 [-3.82,-
0.40]
2.0% 2.0% 0.01 [-1.34,1.37] 0.09
Major bleeding 5.1% 5.2% -0.08 [-2.25,2.09] 9.2% 8.2% 0.94 [-1.79,3.68] 0.62
Definite/probable stent thrombosis* 2.5% 5.7%
-3.22 [-5.39,-
1.04]
2.1% 2.2% -0.08 [-1.60,1.44] 0.12
MACE† 4.5% 7.3%
-2.78 [-5.14,-
0.41]
5.8% 5.2% 0.60 [-1.60,2.80] 0.03
Net adverse clinical events‡ 8.6% 10.8% -2.25 [-5.18,0.68] 13.6% 11.0% 2.59 [-0.56,5.74] 0.03
*By ARC definition; †Death, reinfarction, ischemic TVR or stroke; ‡MACE or major bleeding
